Company Announcements

Acquisition

Source: RNS
RNS Number : 5953C
Scapa Group PLC
02 October 2018
 

 

2 October 2018

LEI No. 213800QIPVTK5ES5UU36

 

 

Scapa Group plc ("Scapa" or "the Group")

 

 

Completion of Acquisition of Systagenix Advanced Wound Dressing Facility in Gargrave

Entering a 5-year exclusive manufacturing and supply agreement

 

Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018.  In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.

 

 

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

 

 0161 301 7430

Numis Securities Limited

(Nominated Adviser and Joint Broker)

Richard Thomas/Mark Lander

 020 7260 1000

 

 

 

Berenberg

(Joint Broker)

Chris Bowman

 

Weber Shandwick Financial PR

Nick Oborne

 

 020 3207 7800

 

 

 

020 7067 0000

                         


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQBUBDGRSGBGIB